BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Musters A, Assaf A, Gerlag DM, Tak PP, Tas SW. Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease. Front Immunol 2015;6:625. [PMID: 26697019 DOI: 10.3389/fimmu.2015.00625] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Musters A, Tas SW. Room for improvement in clinical trials for rare diseases. Nat Rev Rheumatol 2020;16:131-2. [PMID: 31996788 DOI: 10.1038/s41584-020-0376-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hesse MA, Block LM, Israel JS, Poore SO. Surgical Management of Massive Lower Extremity Lymphedema Secondary to Castleman's Disease. Plast Reconstr Surg Glob Open 2017;5:e1622. [PMID: 29632793 DOI: 10.1097/GOX.0000000000001622] [Reference Citation Analysis]
3 Drogou F, Netboute A, Giai J, Dode X, Darmon D, Kassai B, Letrilliart L. Off-label drug prescriptions in French general practice: a cross-sectional study. BMJ Open 2019;9:e026076. [PMID: 30967407 DOI: 10.1136/bmjopen-2018-026076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Cheng JL, Cui J, Wang Y, Xu ZZ, Liu F, Liang SB, Tian H. Unicentric Castleman disease presenting as a retroperitoneal peripancreatic mass: A report of two cases and review of literature. World J Gastroenterol 2018; 24(34): 3958-3964 [PMID: 30228787 DOI: 10.3748/wjg.v24.i34.3958] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
5 Zhou YX, Ji Y, Wu S. A CARE-compliant article: Unicentric Castleman disease presenting as a retroperitoneal mass of the upper edge of the pancreas: A case report. Medicine (Baltimore) 2020;99:e19515. [PMID: 32176100 DOI: 10.1097/MD.0000000000019515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Rusz CM, Ősz BE, Jîtcă G, Miklos A, Bătrînu MG, Imre S. Off-Label Medication: From a Simple Concept to Complex Practical Aspects. Int J Environ Res Public Health 2021;18:10447. [PMID: 34639747 DOI: 10.3390/ijerph181910447] [Reference Citation Analysis]
7 Abid MB, Peck R, Abid MA, Al-Sakkaf W, Zhang Y, Dunnill GS, Staines K, Sequeiros IM, Lowry L. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease? Hematol Oncol 2018;36:320-3. [PMID: 28401573 DOI: 10.1002/hon.2420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
8 Carroll MB. Tocilizumab in the treatment of myocardial infarction. Mod Rheumatol 2018;28:733-5. [PMID: 29334841 DOI: 10.1080/14397595.2018.1427457] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
9 Linkhorn H, van der Meer G, Gruber M, Mahadevan M. Castleman's disease: An unusually young presentation resulting in delayed diagnosis of a neck mass. International Journal of Pediatric Otorhinolaryngology 2016;86:90-2. [DOI: 10.1016/j.ijporl.2016.04.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]